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Abstract
Background: In Africa, tuberculous meningitis (TBM) is an important opportunistic infection in
HIV-positive patients. Current diagnostic tools for TBM perform sub-optimally. In particular, the
rapid diagnosis of TBM is challenging because smear microscopy has a low yield and PCR is not
widely available in resource-poor settings.
Methods: We evaluated the performance outcome of a novel standardized lipoarabinomannan
(LAM) antigen-detection assay, using archived cerebrospinal fluid samples, in 50 African TBM
suspects of whom 68% were HIV-positive.
Results: Of the 50 participants 14, 23 and 13 patients had definite, probable and non-TBM,
respectively. In the non-TB group there were 5 HIV positive patients who were lost to follow-up
and in whom concomitant infection with Mycobacterium tuberculosis could not be definitively
excluded. The test sensitivities and specificities were as follows: LAM assay 64% and 69% (cut-point
0.22), smear microscopy 0% and 100% and PCR 93% and 77%, respectively.
Conclusion:  In this preliminary proof-of-concept study, a rapid diagnosis of TBM could be
achieved using LAM antigen detection. Although specificity was sub-optimal, the estimates provided
here may be unreliable because of a classification bias inherent in the study design where it was not
possible to exclude TBM in the presumed non-TBM cases owing to a lack of clinical follow-up. As
PCR is largely unavailable, the LAM assay may well prove to be a useful adjunct for the rapid
diagnosis of TBM in high HIV-incidence settings. These preliminary results justify further enquiry
and prospective studies are now required to definitively establish the place of this technology for
the diagnosis of TBM.
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Background
Tuberculosis is increasing in Africa [1], where HIV infec-
tion has fuelled an increasing prevalence of pulmonary
and extra-pulmonary tuberculosis (TB) including tubercu-
lous meningitis (TBM) [2,3]. In HIV-endemic settings, a
common clinical dilemma in patients with neurological
symptoms and cerebrospinal fluid (CSF) abnormalities,
even when an alternative diagnosis is made, is whether the
patient has tuberculosis. Biochemistry and cell counts are
unreliable in HIV+ve patients, PCR is not widely availa-
ble, smear microscopy of the CSF has a poor sensitivity
(~5%) and culture results are delayed for several weeks
[4]. Thus, the diagnosis of TBM, which is associated with
substantial morbidity and mortality, is challenging in
high HIV-incidence settings where current tools perform
poorly. There is an urgent need to find alternative rapid
ways to diagnose TBM. Although PCR is a useful rule-in
test (60% sensitivity and 98% specificity); it is expensive,
technically demanding and it not widely available in
resource-poor settings. Alternative methods such as liq-
uid-based culture provide results only after several weeks
[5-7] and gas chromatography for tuberculostearic acid is
expensive and has limited availability even in resource-
rich settings [8]. The utility of quantitative antigen-specific
T cell responses though recently described [9] has not
been validated in clinical trials and is untested in TBM.
Lipoarabinomannan (LAM) is a glycolipid forming part of
the mycobacterial cell wall. It has several immunomodu-
latory effects including interference with macrophage acti-
vation and antigen processing [10-13]. Serum LAM
antibody responses have previously been evaluated as a
diagnostic test for tuberculosis [14]. The performance out-
comes of several other mycobacterial antigen and anti-
body detection kits have been variable, with sensitivities
of 60 to 90% [14-19]. Zhang et al evaluated serum LAM
antigen in patients with extra-pulmonary tuberculosis,
including three patients with TBM, and reported a sensi-
tivity of 26.7% in the extra-pulmonary tuberculosis group
[20]. More recently, a novel standardized ELISA-based
assay was developed to detect LAM antigen in urine [21-
23]. Significantly, a prototype point-of-care immuno-
chromatographic strip test format is now in clinical trials
using urine, sputum and saliva. However, the commer-
cially available LAM antigen-detection assay has not pre-
viously been evaluated in CSF. To investigate the possible
utility of this novel technology for the diagnosis of TBM
we performed a preliminary study using archived CSF
samples from 50 TBM suspects [24].
Methods
Patients
Following ethical approval from the Biomedical Research
Ethics Administration of the University of Kwazulu-Natal,
(consent from patients was not obtained for this retro-
spective study), LAM antigen levels were measured in CSF
samples obtained by lumbar puncture, stored for the past
three years at -70°C, from 50 consecutively-recruited
untreated TBM suspects referred to a tertiary institution in
Durban, South Africa between January 2004 and Decem-
ber 2005. The culture, PCR and microscopy tests were per-
formed on the fresh samples at the time of recruitment,
while the LAM detection was done on stored frozen sam-
ples. The microbiological results have been described in a
previous publication [24]. Approximately 30% of patients
referred to our unit per annum (686 admissions for year
2005) have neurological tuberculosis and 80% of these
are HIV positive. CD4 counts were not available at our
centre at the time of HIV testing. After diagnostic work-up
and re-review of patient notes, and follow-up data, 50
patients were classified as:
(1) Definite TBM if the CSF culture was positive for M.
tuberculosis (the gold standard).
(2)  Probable TBM if the clinical, CSF and radiological
findings were consistent with TBM, but the culture was
negative and alternate aetiologies were excluded. All
patients in this category received empiric anti-TB treat-
ment.
(3) Non-TB if another aetiology was found to explain the
clinical presentation and no anti-TB treatment was
administered. However, in five HIV positive patients, no
follow-up was available and thus the concomitant pres-
ence of M. tuberculosis infection could not be excluded.
CSF testing
The following tests were applied to all CSF samples to
rule-in or exclude other diseases: real-time PCR for M.
tuberculosis [24], antigen-detection test for cryptococcus,
serology for syphilis and cysticercosis, and PCR for herpes
viruses (Herpes Simplex virus 1 & 2, cytomegalovirus,
CMV, Varicella Zoster virus).
LAM antigen was measured using an ELISA kit (Clearview®
TB ELISA, Inverness Medical Innovations, USA). The sam-
ples were thawed and allowed to equilibrate to room tem-
perature. After an initial heating step to separate antigen-
antibody complexes, CSF samples were seeded, in dupli-
cate, into 96 well plates coated with anti-LAM antibodies.
Following this an ELISA was done to measure optical den-
sity (OD) determined by a technician blinded to patient
details. The LAM concentrations were extrapolated from a
standard curve constructed from two-fold serial dilutions
(8 in total ranging from 10 to 0.08 ng/ml) of the LAM
antigen (20 ng/ml), supplied by the manufacturer. To
evaluate the clinical utility of the new test, a comparative
clinical predictive score was applied as defined by
Thwaites et al [25] using age, duration of symptoms, totalCerebrospinal Fluid Research 2009, 6:13 http://www.cerebrospinalfluidresearch.com/content/6/1/13
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blood white cell count, percentage neutrophils in CSF and
total cell count in CSF, from which a score was derived
which if <4 predicted for TBM.
Data analysis
Statistical analysis was conducted using STATA-10. In the
definite TBM group (1), for the sensitivity calculation, the
number of culture positive samples (n = 14) served as the
denominator and for specificity calculation the number of
non-TB samples (n = 13) served as the denominator. In
the probable TBM group (2), the number of probable
TBM cases (n = 23) served as the denominator for the sen-
sitivity calculation. For the specificity calculation, the
number of non-TBM samples (n = 13) served as the
denominator. The manufacturer-recommended cut-off
point for urine samples was used: if the OD was > 0.1
above the OD of the negative control, the patient sample
was regarded as being positive. An additional analysis was
conducted using area under the receiver operating curve
(ROC) derived with the OD cut-off point > 0.22 above the
negative control for a positive test result. Performance
data were re-derived using this cut-off point.
Results
All the patients were black African (mean age of 30.3
years; 60% female; 34/50 (68%) were HIV positive, eight
patients HIV (16%) status was unknown and eight
patients were HIV negative (16%). All except three
patients had AIDS defining illnesses such as extra-pulmo-
nary tuberculosis, cryptococcal meningitis, cerebral toxo-
plasmosis, CMV encephalopathy or disseminated herpes
zoster. Of the 50 participants, there were 14 patients in the
definite group (1), 23 in the probable group (2) and 13
patients in the non TBM group (3). The clinical changes in
the CSF for the three patient groups are presented in Table
1. The 13 non-TBM patients (group 3) had the following
diagnoses: cryptococcal meningitis (n = 4), cerebral toxo-
plasmosis (n = 2), viral meningitis (n = 5: CMV = 2, herpes
= 1, HIV = 2), 1 acute demyelinating encephalomyelitis
and 1 epilepsy.
Of the 14 culture-positive samples (group 1), 13 were also
positive by real-time PCR. A further 14 samples were PCR
positive for M. tuberculosis DNA, but culture negative. Of
these, 11 were in the TBM probable group and three were
in the non-TBM group. None of the samples were smear
positive, the test performance outcomes were similar in
HIV positive and HIV negative groups, and there was no
correlation between LAM antigen levels and CSF bio-
chemical or cellular parameters (data not shown). The
definite TB group (n = 14) consisted of nine LAM antigen
positive and five LAM negative CSF samples. The probable
TBM group (n = 23) consisted of six LAM positive and 17
LAM negative samples. In the non-TB group (n = 13) there
were five LAM positive and eight negative (Table 2).
The PCR sensitivities and specificities for the LAM antigen
assay for groups 1 and 2 are shown in Table 3. In the def-
inite TBM group, the sensitivity and specificity of the LAM
antigen testing was 64% and 69% (when using the
receiver operating characteristic (ROC) defined cut-point)
respectively whereas the corresponding figures for the
PCR assay were 93% and 77% respectively. The smear
microscopy when 3 organisms were considered positive,
was 0.0. A ROC curve was derived comparing definite
TBM and non-TBM groups (Figure 1). When the sensitiv-
ity of the manufacturers and the study-derived OD cut-off
points were compared, there was no difference (64%
using both 0.1 and 0.22 OD cut-off points). The specifi-
city increased from 62% to 69%.
Discussion
The LAM antigen-detection test, a potential test for TBM,
is a rapid and relatively simple assay. In resource-poor set-
tings, the availability of PCR is extremely limited, and
thus smear microscopy for M. tuberculosis is the only rapid
way to diagnose TBM. There have been several recent
reports evaluating urinary LAM antigen as a diagnostic test
for the diagnosis of pulmonary tuberculosis reporting sen-
sitivities in the region of 60% and specificities of 88 to
96% [21-23,26]. In our study, compared to smear micro-
Table 1: Clinical characteristics of the cerebrospinal fluid in the definite, probable and non-tuberculous meningitis (TBM) groups.
Diagnosis Protein (g/l) Lymphocyte count (cells/ml) Neutrophil count (cells/ml) Glucose (mmol/l)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Definite TBM (14) 1.8 (1.58) 64.3 (101.50) 74.3 (135.56) 1.4 (0.69)
Probable TBM (23) 1.5 (1.67) 32.4 (54.67) 123.7 (285.4) 2.9 (1.08)
Non-TBM (13) 0.9 (1.12) 66.0 (165.34 12.6 (16.4) 2.9 (1.01)
Total (50) 1.4 (1.52) 50.1 (105.08) 81.0 (208.86) 2.4 (1.17)Cerebrospinal Fluid Research 2009, 6:13 http://www.cerebrospinalfluidresearch.com/content/6/1/13
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scopy, which identified none of the TBM cases, the LAM
ELISA detected nine out of 14 definite TBM cases. We
speculate that the five undetected cases may have been
due to paucibacillary disease, non-specific protein bind-
ing of antibody, or failure to separate CSF antigen-anti-
body complexes despite an intermediate heating step.
However, significantly, the specificity was only 64% (five
LAM+ve cases in the non-TB group). How do we explain
these results? Four out of five of these cases were HIV pos-
itive and as the patients had been immediately discharged
to remote referral centres after their diagnostic work-up
no follow-up data was available. Thus, we cannot be sure
that some or all of these patients had dual infection (iden-
tified alternative aetiology and concomitant early TBM),
which is well-recognised in HIV positive patients with
meningitis [27,28]. It is also possible that LAM antibody
may have cross-reacted with mannose residues found in
other organisms including cryptoccus neoformans. (1 out of
5 positive LAM assays in the non-TB group had cryptococ-
cal meningitis) [29]. Thus classification bias rather than
poor test performance could have accounted for the sub-
optimal test specificity. Given the retrospective nature of
the study it is impossible to determine which of these pos-
sibilities is correct and it is entirely possible that the test
may lack sufficient specificity to be clinically useful. Thus,
a prospective study is now required to clarify the true spe-
cificity of the LAM assay, paying careful attention to case
definition and classification.
Several factors may modulate the level and hence detec-
tion of LAM antigen in biological samples. The influence
of the blood brain barrier (BBB) permeability on LAM
Table 2: Numbers of patients positive and negative for 
lipoarabinomannan (LAM) in the CSF in the definite, probable 
and non-tuberculous meningitis (TBM) groups
Diagnosis (Number) LAM +ve (%) LAM -ve
(%)
Definite TBM (14) 9 (64) 5 (36)
Probable TBM (23) 6 (26) 17 (74)
Non-TBM (13) 5 (38.5) 8 (61.5)
Table 3: Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) values for PCR test and 
lipoarabinomannan (LAM) ELISA assay in patients with definite and probable tuberculous meningitis (TBM).
Definite TBM (culture +ve), n = 14 Probable TBM, n = 23
percentage 95% CI 95% CI
PCR Sens 93 64 - 95 48 27 - 69
Spec 77 46 - 94 77 46 - 94
PPV 81 54 - 95 79 49 - 94
NPV 91 57 - 100 46 25 - 67
LAM ELISA using 0.1 cut-off point# Sens 64 36 - 86 26 11 - 49
Spec 62 32 - 85 62 32 - 85
PPV 64 33 - 85 55 16 - 54
NPV 62 36 - 86 32 25 - 82
LAM ELISA using AUC-derived 0.22 cut-off point$ Sens 64 36 - 86 22 08 - 44
Spec 69 39 - 90 69 39 - 90
PPV 69 39 - 90 56 23 - 85
NPV 64 36 - 86 33 17 - 54
AUC 0.60 n/a 0.70 n/a
# the manufacturer-recommended cut-off point for testing of urine samples, 0.1; $ the area under the receiver operating curve-derived cut-point, 
0.22.Cerebrospinal Fluid Research 2009, 6:13 http://www.cerebrospinalfluidresearch.com/content/6/1/13
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sensitivity in CSF is uncertain and has not been previously
investigated. The frequency of LAM antigenemia or a
measure of the IgG-albumin index could potentially have
given us an idea about BBB function. However, this was
not possible given the retrospective study design. The
widely variable urine LAM sensitivity (17.8% to 80.3%)
reported in several publications may be related to the
severity of immune suppression in HIV-positive patients
[22,23,26,30]. This aspect deserves further investigation
in future studies.
It is possible that the LAM ELISA will have clinical utility
in a resource-poor setting because it has incremental value
over and above that of simple clinical and laboratory
parameters, including a previously published bio-clinical
score. Indeed, the clinical score (Thwaites et al) [25],
devised primarily to distinguish bacterial meningitis from
TBM, had a specificity of only 10% for the diagnosis of
TBM. The rapidity of the LAM test (approximately 2
hours), despite a sensitivity of only 64%, makes it a poten-
tially useful rule-in test in high-burden settings. Here the
diagnosis is largely clinical and the CSF picture may be
atypical, and even acellular, in HIV positive individuals
[4,24].
Conclusion
This preliminary data obtained through analysis of a
small number of archived samples indicate that despite its
modest sensitivity, the LAM assay, with a 60% positive
predictive value may be promising for the rapid diagnosis
of TBM in a resource-poor, high-HIV prevalence tertiary
setting. Prospective trials are now warranted in different
geographical and clinical settings to clarify the utility and
specificity of this assay for the diagnosis of TBM.
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